AGP Executive Report
Last update: 8 hours agoTravel & Health Access: ETIAS rollout for non-EU visitors to the Schengen area has been delayed, adding more uncertainty for summer travel plans after EU border rules already triggered airport delays. Antibiotic Resistance: EU/EEA health payers are pushing shared pricing and reimbursement models as a practical lever against antimicrobial resistance, with a Nordic cross-border purchasing and supplier remuneration approach flagged for possible rollout. Transplant Care: Hansa Biopharma says its €115m Idefirix licensing deal with SERB is now closed, aiming to expand access in the EU and beyond for desensitisation in highly sensitised kidney transplant patients. Osteoporosis Treatment: The European Commission has authorized CinnaGen’s teriparatide biosimilar Zandoriah across EU27 plus Iceland, Liechtenstein and Norway, supporting broader availability for adult osteoporosis. Local Context: Liechtenstein appears among the world’s most rural countries by population share, a reminder that health planning and services can look different in smaller, more rural settings. Trade & Health Policy Links: EFTA and Vietnam concluded a long-running free trade agreement that also covers sanitary and phytosanitary measures—relevant for how food, agriculture and health standards move across borders.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
